Lennon et al. documented, both in vitro and in vivo, that the inhibition of EPHB4/ephrin-B2 signaling in conjunction with RT shifts the balance towards the anti-tumor responses, reducing PDAC tumor growth and limiting the fibrotic response [59]. The gene discussed is EPHB4; the disease is neoplasm.